Roche’s HDL Agent Proves Safe In Phase II
This article was originally published in The Pink Sheet Daily
R1658 deemed different than Pfizer’s troubled torcetrapib.
You may also be interested in...
R1658 could raise "good" cholesterol, firm says during 2007 financial review.
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.